InspireMD (NSPR) announced that the first patient has been enrolled in the company’s CGUARDIANS II clinical trial evaluating its CGuard Prime Carotid Stent System in patients undergoing carotid artery stenting via the Transcarotid Artery Revascularization approach. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck serves as both the site principal investigator as well as a co-lead investigator of the CGUARDIANS II study.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSPR:
- InspireMD Strengthens Leadership with Scott R. Ward Appointment
- InspireMD Inc. Faces Financial Uncertainty Amidst Ongoing Losses and Cash Flow Challenges
- InspireMD Inc. Reports Q3 2024 Financial Results
- InspireMD Achieves Record Q3 Revenue with CGuard Success
- InspireMD reports Q3 EPS (16c) vs (15c) last year